Morpholino

MO1-kcna1a

ID
ZDB-MRPHLNO-190711-1
Name
MO1-kcna1a
Previous Names
None
Target
Sequence
5' - GTTGTCCCCAGCCACAACTGTCATC - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Translation-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-kcna1a
No data available
Phenotype
Phenotype resulting from MO1-kcna1a
No data available
Phenotype of all Fish created by or utilizing MO1-kcna1a
Phenotype Fish Conditions Figures
oxidative phosphorylation increased process quality, abnormal TL + MO1-kcna1a + MO4-tp53 constant dark Fig. 1,  Fig. 2 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: EC 3.5.1.98 (histone deacetylase) inhibitor Fig. 7 from Ibhazehiebo et al., 2018
cellular respiration increased process quality, abnormal TL + MO1-kcna1a + MO4-tp53 constant dark Fig. 1,  Fig. 2,  Fig. 4 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: levetiracetam Fig. 4 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: eslicarbazepine acetate Fig. 2 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: oxcarbazepine Fig. 4 from Ibhazehiebo et al., 2018
locomotory behavior increased occurrence, abnormal TL + MO1-kcna1a + MO4-tp53 constant dark Fig. 4 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: primidone Fig. 2 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: vorinostat Fig. 3,  Fig. 5 from Ibhazehiebo et al., 2018
locomotory behavior increased occurrence, abnormal TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: topiramate Fig. 4 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: topiramate Fig. 4 from Ibhazehiebo et al., 2018
oxidative phosphorylation process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: primidone Fig. 2 from Ibhazehiebo et al., 2018
oxidative phosphorylation process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: eslicarbazepine acetate Fig. 2 from Ibhazehiebo et al., 2018
optic tectum transmission of nerve impulse occurrence, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: vorinostat Fig. 6 with image from Ibhazehiebo et al., 2018
oxidative phosphorylation process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: rufinamide Fig. 2 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: valproic acid Fig. 3 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: rufinamide Fig. 2 from Ibhazehiebo et al., 2018
locomotory behavior increased occurrence, abnormal TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: oxcarbazepine Fig. 4 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 chemical treatment by environment: MC1568 Fig. 7 from Ibhazehiebo et al., 2018
optic tectum transmission of nerve impulse increased occurrence, abnormal TL + MO1-kcna1a + MO4-tp53 constant dark Fig. 6 with image from Ibhazehiebo et al., 2018
locomotory behavior increased occurrence, abnormal TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: levetiracetam Fig. 4 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: lamotrigine Fig. 4 from Ibhazehiebo et al., 2018
cellular respiration process quality, ameliorated TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: belinostat Fig. 7 from Ibhazehiebo et al., 2018
locomotory behavior increased occurrence, abnormal TL + MO1-kcna1a + MO4-tp53 constant dark, chemical treatment by environment: lamotrigine Fig. 4 from Ibhazehiebo et al., 2018
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.